EPRX.TO Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector...

Stats
Šios dienos apimtis	15 050.00
Vidutinė apimtis	68 096.00
Rinkos kapitalizacija	132.87M
EPS	$0 ( 2024-04-03 )
Kita pelno data	( $-0.340 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.19
ATR14	$0.0180 (0.48%)

Eupraxia Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
TCL-A.TO	0.937
CFP.TO	0.902
AQN.TO	0.902
AW-UN.TO	0.901
BLX.TO	0.894
TULB.TO	0.893
WTE.TO	0.893
ESGF.TO	0.89
NPI.TO	0.89
BIP-UN.TO	0.889

10 Labiausiai neigiamai susiję koreliacijos
SUSA.TO	-0.93
IAF-PI.TO	-0.883
OBE.TO	-0.88
MEG.TO	-0.875
PEY.TO	-0.87
CTZ.V	-0.869
PKI.TO	-0.861
RQK.TO	-0.85
URB.TO	-0.843
VLE.TO	-0.842

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Eupraxia Pharmaceuticals Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-209 911 (0.00 %)
EPS:	$-1.580

FY	2023
Pajamos:	$0
Bruto pelnas:	$-209 911 (0.00 %)
EPS:	$-1.580

FY	2022
Pajamos:	$0
Bruto pelnas:	$-193 273 (0.00 %)
EPS:	$-1.210

Financial Reports:

No articles found.

Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.